Literature DB >> 12434403

Preliminary pharmacokinetic study of different preparations of acyclovir with beta-cyclodextrin.

Javiana Luengo1, Teobaldo Aránguiz, Jacqueline Sepúlveda, Luis Hernández, Carlos Von Plessing.   

Abstract

Acyclovir has absorption problems, because of its low solubility and/or its saturable absorption mechanism, that take place in the small intestine in a passive, variable, and incomplete manner. The oral bioavailability of acyclovir is thereby affected and reaches only 15-30%. The purpose of this study was to investigate the possibility of increasing the oral availability of acyclovir by forming inclusion complexes of acyclovir with beta-cyclodextrin. Acyclovir, its complex (1:1) with beta-cyclodextrin (acyclovir-beta-cyclodextrin complex), and a 50:50 mixture of acyclovir and the inclusion complex (acyclovir/complex mixture) as an aqueous suspension were administered intraintestinally to male Sprague-Dawley rats in doses equivalent to an acyclovir dose of 75 mg/kg. Sequential samples of plasma were taken by microdialysis. The samples were analyzed by high-performance liquid chromatography with ultraviolet detection. Plasma concentration versus time curves show that the complex and the mixture of acyclovir/complex have a higher bioavailability and a pharmacokinetic profile than that of the drug itself. Copyright 2002 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 91:2593-2598, 2002

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12434403     DOI: 10.1002/jps.10245

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  9 in total

1.  Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits.

Authors:  Ismail A Attia; Sanaa A El-Gizawy; Medhat A Fouda; Ahmed M Donia
Journal:  AAPS PharmSciTech       Date:  2007-12-14       Impact factor: 3.246

Review 2.  Impact of excipient interactions on drug bioavailability from solid dosage forms.

Authors:  Ravikiran Panakanti; Ajit S Narang
Journal:  Pharm Res       Date:  2012-05-19       Impact factor: 4.200

3.  Cellulose Acetate 398-10 Asymmetric Membrane Capsules for Osmotically Regulated Delivery of Acyclovir.

Authors:  Alka Sonkar; Anil Kumar; Kamla Pathak
Journal:  J Pharm (Cairo)       Date:  2016-02-11

4.  Development of a gastroretentive delivery system for acyclovir by 3D printing technology and its in vivo pharmacokinetic evaluation in Beagle dogs.

Authors:  Soyoung Shin; Tae Hwan Kim; Seok Won Jeong; Seung Eun Chung; Da Young Lee; Do-Hyung Kim; Beom Soo Shin
Journal:  PLoS One       Date:  2019-05-15       Impact factor: 3.240

5.  SARS-CoV-2 main protease (3CLpro) interaction with acyclovir antiviral drug/methyl-β-cyclodextrin complex: Physiochemical characterization and molecular docking.

Authors:  Sonaimuthu Mohandoss; Ramaraj Sukanya; Sivarasan Ganesan; Fatemah H Alkallas; Amira Ben Gouider Trabelsi; Fedor V Kusmartsev; Kuppu Sakthi Velu; Thambusamy Stalin; Huang-Mu Lo; Yong Rok Lee
Journal:  J Mol Liq       Date:  2022-09-09       Impact factor: 6.633

6.  Transdermal Film Loaded with Garlic Oil-Acyclovir Nanoemulsion to Overcome Barriers for Its Use in Alleviating Cold Sore Conditions.

Authors:  Alshaimaa M Almehmady; Sarah A Ali
Journal:  Pharmaceutics       Date:  2021-05-07       Impact factor: 6.321

7.  Comparison of Aqueous and 1-Octanol Solubility as well as Liquid-Liquid Distribution of Acyclovir Derivatives and Their Complexes with Hydroxypropyl-β-Cyclodextrin.

Authors:  Małgorzata Koźbiał; Paweł Gierycz
Journal:  J Solution Chem       Date:  2013-04-26       Impact factor: 1.677

8.  In vitro Evaluation of Acyclovir/Chitosan Floating Systems.

Authors:  Roberto Ruiz-Caro; María D Veiga
Journal:  Materials (Basel)       Date:  2010-12-06       Impact factor: 3.623

Review 9.  Cyclodextrins in Antiviral Therapeutics and Vaccines.

Authors:  Susana Santos Braga; Jéssica S Barbosa; Nádia E Santos; Firas El-Saleh; Filipe A Almeida Paz
Journal:  Pharmaceutics       Date:  2021-03-19       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.